Klaria raises $11M in rights issue, a third settled against debt
What's the deal? Swedish drug developer KlariaDealroom has a profile for this one. Try Dealroom → Pharma Holding raised approximately US$13.4M before costs in a rights issue of units, the company said on November 13, 2026. Of that total, roughly US$4.51M will be paid by way of set-off against claims on the company — reducing debt rather than adding cash.
What does Klaria do? It makes a fast-dissolving oral film designed to deliver established treatments without a conventional tablet, with a migraine product moving toward European commercialisation.
The details: The issue drew subscriptions worth about US$11M, or 61.4% of the offering. Vator SecuritiesDealroom has a profile for this one. Try Dealroom → subscribed for a further US$2.48M under its underwriting commitment.
Why now? The raise landed about three-quarters of its roughly US$17.8M target as Klaria prepares to commercialise its migraine product with partner CNX TherapeuticsDealroom has a profile for this one. Try Dealroom → and explores a potential US partner. The company had flagged a working-capital shortfall and taken bridge loans to meet near-term obligations.
What could go wrong? After the set-off, cash proceeds fall to roughly US$8.92M before issue costs and loan repayments — well below the headline figure. The financing cuts liabilities, but leaves substantially less new liquidity for operations and development, and commercial revenues are not yet established.
Chairman Fredrik Hübinette said the proceeds "strengthen the Company's financial position, settle short-term liabilities and enable us to execute our commercial strategy."
The signal: For a clinical-stage developer, the structure matters as much as the number. Klaria swaps a strained balance sheet for a lighter one, but the gap between the US$13.4M headline and the actual cash intake shows how much of this round is about survival ahead of a commercial test it has yet to pass.
Read more: news.cision.com
Image credit: Generated with Gemini
